

# Health Economics & Outcomes Research Fellowships

2024-2026




# Novartis is a world leader in the research and development of products to protect and improve health and well-being.

Novartis was created in 1996 from the merger of the Swiss companies Ciba-Geigy and Sandoz. Novartis Pharmaceuticals is dedicated to discovering, developing, manufacturing, and marketing prescription drugs to prevent and cure diseases, to ease suffering and to enhance quality of life. Novartis' portfolio of products is directed toward cardiovascular, multiple sclerosis, immunology, hepatology, and dermatology, organ transplantation, ophthalmology, oncology and hematology, and other therapeutic areas.


Novartis, derived from the Latin novae artes, meaning "new skills," is committed to using new skills to improve health and well-being through innovative products and services. Recognizing an increasing need for outcomes information, resources and expertise, the Health Economics & Outcomes Research (HEOR) departments at Novartis strive to be best-in-class in the generation of outcomes evidence that demonstrates value and optimizes patient access to Novartis products. This is accomplished through execution of burden

and cost-of-illness studies, economic evaluations alongside clinical trials, comparative effectiveness research, cost-effectiveness analyses, prospective observational studies such as effectiveness registries, retrospective claims database analyses and patient-reported outcomes research.



### **Purpose**

The Health Economics & Outcomes Research (HEOR) Fellowship Program provides training and hands-on experience in a broad range of health economics, outcomes research and comparative effectiveness research (CER) opportunities. This 2-year program is structured to allow the Fellows to gain proficiency in the field of health economics, outcomes research and CER as conducted in academic, managed care, hospital, health policy and/or pharmaceutical industry settings.



#### **Overview**

Novartis Pharmaceuticals Corporation is pleased to offer three 2-year Health Economics & Outcomes Research (HEOR) Fellowship positions for the 2024-2026 cycle.

The objective of the first year is to educate the fellow on general principles and methods applied in health economics and outcomes research. Concurrently, the fellow will participate in ongoing outcomes research projects at the first year fellowship site. All Fellows will spend the second year of the Fellowship at the US-based headquarters of Novartis Pharmaceuticals Corporation located in East Hanover, New Jersey.


While at Novartis, "field-based" training will be undertaken as part of the Fellowship training. Fellows will participate in health economics and outcomes research projects and gain experience in how a pharmaceutical manufacturer uses clinical, economic, and humanistic data to support the development and commercialization of its products, with opportunities in dermatology, cardiovascular franchises and renal franchises.

The fellowship positions differ by first-year site requirements and type of experience offered. Each position is described in this brochure. Compensation includes a competitive stipend, basic medical insurance, holiday and vacation time, plus other benefits associated with each specific academic/managed care institution.

# First-Year Fellowship Sites for 2-Year Programs (3 Positions):

- Baylor Scott & White Health, Temple, TX/ The University of Texas at Austin, Austin, TX (1 position)
- Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA (1 position)
- University of Pittsburgh School of Pharmacy/ UPMC Health Plan, Pittsburgh, PA (1 position)

# Fellowship Alumni: Where Are They Now?



#### **Contact**

Please contact current Fellows for any site-specific questions (contact information provided on subsequent pages).

For inquiries regarding general application or interview process, please contact:

Batul Electricwala, PhD, BPharm Director, HE&OR and HE&OR Fellowship Director East Hanover, NJ usheor.fellowship@novartis.com



# Novartis Pharmaceuticals Corporation/ Baylor Scott & White Health/ The University of Texas at Austin



#### **Fellowship Sites & Preceptors**

#### **Baylor Scott & White Health**

Paul Godley, PharmD, FASHP, BCPS, Director of Pharmacy, Ambulatory & Speciality Clinical Pharmacy Services, Temple, TX

#### The University of Texas at Austin College of Pharmacy

Chanhyun Park, PhD, MPharm, MEd, RPh, Assistant Professor of Health Outcomes, Austin, TX

#### **Novartis Pharmaceuticals Corporation**

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

#### **Baylor Scott & White Health/The University of Texas**

Baylor Scott & White is an integrated healthcare system in central Texas. The Scott & White Health Plan is a health maintenance organization that has over 400,000 members and is affiliated with the Baylor Scott & White Quality Alliance, the system's accountable care organization, which represents over 6,000 physicians. Baylor Scott & White is affiliated with the College of Medicine, Texas A&M University Health Science Center, and the College of Pharmacy, The University of Texas at Austin.

The Department of Pharmacy at Baylor Scott & White provides progressive and innovative pharmaceutical services in a variety of environments for all components of the institution. Included are clinical and distributive services for the hospital, clinic and health plan, as well as sponsorship of pharmaceutical care programs and ambulatory care clinics focusing on lipid, diabetes and anticoagulation management. Fellows will gain significant understanding of the key issues involved in pharmacy services provided by prescription benefits management and managed care organizations. The integrated character of the institution and the Department of Pharmacy provides significant opportunities for pharmacy practice, research and education.

The Health Outcomes and Pharmacy Practice Division, College of Pharmacy, The University of Texas at Austin, is one of the preeminent educational institutions for pharmacy education in the nation. The college is located in

downtown Austin, and the Fellow is offered the option of pursuing the Master of Science degree in Pharmaceutical Sciences at the University of Texas, Austin. The degree would be granted at the end of the Fellowship provided that the required coursework and thesis have been completed. The recommended course of study is designed to assist the Fellow in coordinating required and recommended coursework along with the Fellowship requirements. However, the coursework is tailored based on individual interests, background and career goals. Additionally, the College is home to TxCORE (Texas Center for Health Outcomes Research and Education), which is a leader in addressing population and individual health through innovative, high-quality research, and education, and serves the community by responding to critical health care issues that impact patients' daily lives. TxCORE combines the strengths of its nationally recognized clinical, pharmacy, social and behavioral, economics, and policy researchers to collect, analyze, and interpret data, and disseminate research findings throughout the many sectors of the health care industry, government, and private sector organizations.

The unique nature of the Baylor Scott & White integrated healthcare system, combined with the pharmacoeconomic expertise at the College of Pharmacy, offers significant opportunity for individuals interested in the Novartis Fellowship experience.

#### **Eligibility**

Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

#### Information

For questions or additional information, please contact:

Xiaoxia (Summer) Wang, PharmD Health Economics & Outcomes Research Fellow Email: xiaoxia.wang@bswhealth.org

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



#### First-Year Fellow: Xiaoxia (Summer) Wang, PharmD

Xiaoxia Wang is a first-year Health Economics & Outcomes Research (HEOR) Fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin (UT Austin). Xiaoxia received her Doctor of Pharmacy degree from the University of South Carolina (USC). Her interest in HEOR stems from her background in managed care and her passion for improved patient clinical outcomes and medical access.

During her time at USC, Xiaoxia participated in several research projects in clinical outcome research and healthcare information technology. Her research projects focused on a variety of different aspects, including cost-effectiveness analysis of Alzheimer's disease medications, medication repurposing of antidiabetic treatments, healthcare disparities, and health service utilization in the oncology area. She enjoyed working across a variety of therapeutic areas and was passionate about clinical outcome research.

Prior to her fellowship, Xiaoxia worked in multiple settings such as retail pharmacy, pharmaceutical company, and consulting company. She has been working as a market access intern at The Kinetix Group (TKG) for more than one year, where she was able to perform secondary research for newly FDA-approved oncology and rare disease treatments and conducted market research to assess the competitive landscape and assist in developing marketing plans. She also participated in business pitches and developed research protocols for real-world evidence projects, and this working experience made her very interested in pharmaceutical company and data analysis.

During the first year, Xiaoxia will collaborate with pharmaceutical companies to conduct clinical outcome and economics studies at BSWH, while supporting the Antimicrobial Stewardship and the P&T Committee. In addition, Xiaoxia is working towards earning a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at the University of Texas at Austin.



#### Second-Year Fellow: Karishma Thakkar, PharmD

Karishma Thakkar is the second-year Health Economics & Outcomes Research (HEOR) fellow with Novartis Pharmaceuticals Corporation, Baylor Scott & White Health (BSWH), and the University of Texas at Austin.

Karishma received her Doctor of Pharmacy degree from the University of Houston College of Pharmacy and brings to the fellowship her valuable experiences from managed care, research, hospital, and specialty pharmacy. Prior to the fellowship, Karishma interned at the Texas Children's Health Plan, where she supported the Director of Pharmacy in strategizing ways to improve key accountable care organization metrics and health outcomes for their members. She also was involved in various research projects such as a systematic literature review and quality improvement projects where she gained experience formulating search strategies, designing data extraction protocols, and analyzing results.

During her first year at BSWH and UT Austin, she led an industry sponsored study focused on the patient journey with prurigo nodularis and supported an implementation science project assessing physician confidence in outpatient deep vein thrombosis management. She was also able to support a variety of internal research committees such as antimicrobial stewardship committee, diabetes subcommittee and the specialty taskforce, utilizing retrospective claims and electronic health record data. Some of her projects included an analysis of key performance indicators in the BSWH commercial populations, assessing antibiotic prescribing trends and comparing outcomes of antidiabetic medications to drive operational decisions at BSWH. As a result, she presented 4 posters at various conferences including AMCP and ISPOR and is in the process of publishing 2 manuscripts.

In her second year at Novartis, Karishma supports the US HE&OR Cardiovascular, Metabolic and Nephrology team. She works cross-functionally with internal and external stakeholders, working on various parts of a project from concept development to data dissemination dependent on strategic alignment. She is currently involved in multiple projects, including a retrospective claims analysis, economic modeling, and strategic preparation for launch. In addition, Karishma is also working towards earning a Master's degree in Pharmaceutical Science from the Division of Health Outcomes and Pharmacy Practice at UT Austin.

# Novartis Pharmaceuticals Corporation/ Thomas Jefferson University, Jefferson College of Population Health



#### **Fellowship Sites & Preceptors**

#### **Thomas Jefferson University**

Vittorio Maio, PharmD, MS, MSPH, Professor and Director, Health Economics and Outcomes Research Fellowship, Jefferson College of Population Health, Thomas Jefferson University, Philadelphia, PA

#### **Novartis Pharmaceuticals Corporation**

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

#### College of Population Health, Thomas Jefferson University

Established in 2008, the Jefferson College of Population Health (JCPH) is one of six colleges that comprise Thomas Jefferson University, founded in 1824 as Jefferson Medical College. JCPH builds upon the 18-year history of Jefferson's Department of Health Policy and specializes in all key areas of population health-public health, health policy, healthcare quality and safety, and applied health economics and outcomes research (AHEOR). The College has one of the oldest and most established outcomes research Fellowship programs in the country. To date, over 50 individuals have completed JCPH Fellowships and have successfully pursued careers in all sectors of the healthcare industry, including government, pharmacy, insurers and consulting.

During the first year, the Fellow will work in JCPH at the University's Philadelphia Center City campus and be assigned to manage specific outcomes research projects. As a member of the JCPH research team, s/he has the opportunity to attend and present at research meetings, journal clubs, Population Health Forums and sponsored educational programs. S/he may also contribute to any one of several graduate level classes taught by JCPH faculty in the College's public health, AHEOR, health policy, healthcare quality and safety, population health intelligence and population health graduate programs. The Fellow will develop writing skills through completion of a writing seminar, peer review of continuing education articles and authorship of manuscripts for publications edited by American Journal of Medical Quality, Population Health Management, and Population Health Matters.

Networking is also an important activity during the first year. The Fellow will interact with decision makers from both within the University and from a broad variety of organizations, including pharmaceutical and device manufacturers, health plans and other health-related employers. The Fellow will regularly meet with JCPH faculty and staff to discuss research projects and academic experiences, and s/he will be assigned a faculty mentor to coach him/her during the first year. Completion of master's level coursework through JCPH is a formal component of this Fellowship and serves to develop the knowledge and skills required for health economics and outcomes research. The Fellow has the option to complete a fully supported graduate Certificate or Master of Science degree program in public health, population health, population health intelligence, health policy or applied health economics and outcomes research.

The second year of training will take place at Novartis, located in East Hanover, New Jersey. During this time, under the guidance of a Novartis preceptor, the Fellow will work directly with the HEOR department at Novartis for a period of one year in order to further their educational objectives by gaining applied experience in health economics and outcomes research. In addition to project work, the Fellow will participate in meetings to share his or her work and further develop networking and presentation skills.

#### **Eligibility**

Eligible candidates should have an advanced degree in health services research, public health, economics, epidemiology, pharmacy, pharmacy administration or a related discipline. A background in pharmacy or medicine and experience in outcomes research, health economics or another related field of research is preferred. Candidates must have excellent written and verbal communication skills.

#### Information

For questions or additional information, please contact:

Charlene Tugwete, PharmD Health Economics & Outcomes Research Fellow Email: charlene.tugwete@jefferson.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



#### First-Year Fellow: Charlene Tugwete, PharmD

Charlene is a first-year Health Economics & Outcomes Research (HEOR) Fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceuticals Corporation.

Charlene received her Doctor of Pharmacy from the University of Maryland, Baltimore (UMB). Her passion for HEOR developed from her wide range of experiences during her time in pharmacy school. These experiences enriched her understanding and sparked her interest in exploring the intersection of healthcare and economics. Charlene was first introduced to HEOR after participating in the AMCP Local P&T Competition in 2021. She enters the Fellowship with a variety of past experiences in research, managed care, and health policy.

Prior to the fellowship, Charlene contributed to understanding the utilization of Z-codes among oncology patients, aiming to estimate the association between social determinants of health (SDOH) and health utilization using private payer claims data. Additionally, during her Carefirst Blue Cross BlueShield rotation, she gained insight into the US payer model system and formulary decision-making.

During her first year at JCPH, Charlene will be involved in an array of projects, including manuscript writing, claims-based outcomes research, modeling, and patient registry data. Alongside these projects, she will pursue a master's degree in Applied Health Economics and Outcomes Research. Through the JCPH Fellowship, Charlene aspires to build on her knowledge of HEOR and related disciplines to further solidify her skills and contribute to enhancing patient care and access.



#### Second-Year Fellow: Adaeze Amaefule, PharmD

Adaeze Amaefule is the second year Health Economics & Outcomes Research (HEOR) fellow with the Jefferson College of Population Health (JCPH) and Novartis Pharmaceutical Corporation.

Adaeze received her Doctor of Pharmacy from the University of Maryland School of Pharmacy. Her interest in health economics & outcomes research (HEOR) stemmed from her background in public health science, passion for improved patient outcomes, and was also sparked during her internship with Novartis. Prior to the fellowship, she was a medical affairs intern at Novartis, where she was able to work crossfunctionally with the HEOR team. Adaeze completed a rotation with Bristol-Myers Squibb's US HEOR team and Xcenda, where she reviewed protocols for unmet need studies, evaluated data visualization tools for field HEOR use.

During the first year of the fellowship at Jefferson College of Population Health (JCPH), Adaeze furthered her training in HEOR through a variety of research projects which included analyzing administrative claims data, surveys, and registry data. She led outcomes research projects in kidney transplantation, major depressive disorder, employer perspectives, and oncology care quality metrics. Adaeze presented 5 research projects at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Academy of Manage Care Pharmacy (AMCP), and American Society of Clinical Oncology (ASCO).

During her second year of her fellowship at Novartis, Adaeze supports the US HEOR Solid Tumor team by managing research studies through collaboration with cross-function teams in concept development, protocol review, and strategic planning. Her research consists of qualitative research, economic modeling and retrospective claims database analyses. Adaeze is also continuing her coursework towards earning a Master's degree in applied health Economic and Outcome Research from JCPH.

# Novartis Pharmaceuticals Corporation/ University of Pittsburgh School of Pharmacy/UPMC Health Plan (1 position)



UPMC HEALTH PLAN

#### **Fellowship Sites & Preceptors**

**University of Pittsburgh School of Pharmacy** 

Kangho Suh, PharmD, PhD, Assistant Professor, Department of Pharmacy & Therapeutics, Pittsburgh, PA

#### **UPMC Health Plan**

Chester "Bernie" Good, MD, MPH, Senior Medical Director, Center for Value-Based Pharmacy Initiatives, Pittsburgh, PA

Samuel Peasah, PhD, RPh, MBA, Director, Center for Value-Based Pharmacy Initiatives and Associate, Adjunct Associate Professor, University of Pittsburgh School of Pharmacy, Pittsburgh, PA

#### **Novartis Pharmaceuticals Corporation**

Batul Electricwala, PhD, BPharm, Director, HE&OR and HE&OR Fellowship Director, East Hanover, NJ

# The University of Pittsburgh School of Pharmacy/UPMC Health Plan

UPMC Health Plan, headquartered in Pittsburgh, Pennsylvania, is among the nation's fastest-growing health plans. It is owned by the University of Pittsburgh Medical Center (UPMC), a world-renowned integrated health care delivery and financing system. The UPMC Health Plan is committed to providing its members better health, through an evidence-based insurance design and generous pharmacy benefit.

The Center for High-Value Healthcare (CHVHC) is a nonprofit research organization housed within UPMC Health Plan that translates, through research and collaboration, the work of the UPMC Insurance services into evidence-based practice and policy change. The Center for Value-based Pharmacy Initiatives is a center within CHVHC that focuses on value/outcomes-based contracts and pharmacy-related outcomes research in collaboration with the pharmacy department of the Health Plan and other external partners.

University of Pittsburgh is one of the oldest institutions of higher education in the United States. It was ranked as the No. 1 public university in the Northeastern United States in 2020 and is ranked in the top 20 among the nation's top public colleges and universities. At the School of Pharmacy, the Fellow will have the opportunity to earn an online Master of Science in PharmacoAnalytics - Pharmaceutical Outcomes Research. This program provides students with tools and skills necessary to analyze large, healthcare datasets and apply data analytic and pharmacoepidemiology concepts to enhance pharmaceutical use and outcomes. A key feature of this program is competency-based learning, which requires students to demonstrate application of didactic learning through hands-on analysis of realworld data and evidence. Students will develop core competencies related to study design, data collection, data management, data organization, data analysis, and data visualization/communication.

The intersection of managed care, academia, and opportunities to lead outcomes research projects will enable the Pitt Pharmacy and UPMC Health Plan 1st year site to equip the fellow with the necessary skills and abilities to succeed in the 2nd year at Novartis and beyond.

#### **Eligibility**

Eligible candidates must have a doctorate in pharmacy or the combination of an undergraduate degree in pharmacy plus an advanced degree in health services research, public health, health policy, pharmacy, economics, medicine or other related area. Experience in, or at a minimum, exposure to some aspect of outcomes research, health economics or another related field of research is preferred.

#### **Information**

For questions or additional information, please contact:

Kangho Suh, PharmD, PhD Assistant Professor University of Pittsburgh | School of Pharmacy Email: KAS551@pitt.edu

All questions regarding potential visa sponsorship should be directed to the collaborating institution.



#### Assistant Professor: Kangho Suh, PharmD, PhD

Kangho Suh is an Assistant Professor in the Department of Pharmacy & Therapeutics in the School of Pharmacy at University of Pittsburgh. His research areas are in pharmacoepidemiology, health economics, and outcomes research. He received his PharmD from Rutgers University and then completed the Novartis HEOR fellowship at University of Texas at Austin (where he received his MS) and Scott & White Health Plan. Afterwards, he graduated with his PhD from the CHOICE Institute at University of Washington. As a previous fellow, Kangho looks forward to mentoring and growing the next generation of HEOR leaders at Pitt through the Novartis fellowship.

Currently, Kangho's research includes assessing outcomes in drug-associated acute kidney injury, examining comparative and cost-effectiveness in second generation antipsychotics long acting injectables, and evaluating healthcare costs in chronic kidney disease. Additionally, he leads research projects for the Rx Center for Outcomes Research and Practice Implementation Excellence (RxCore) between Pitt Pharmacy and UPMC with the help of graduate students. Furthermore, he is an external member of the Institute for Clinical and Economic Review where he developed the economic models in Amyotrophic Lateral Sclerosis, nonalcoholic steatohepatitis, and currently Metachromatic Leukodystrophy.



Senior Medical Director: Chester "Bernie" Good, MD, MPH

Bernie Good is the Senior Medical Director for the Center for Value-Based Pharmacy Initiatives with UPMC Health Plan, where he provides oversight for the development, implementation, and evaluation of innovative value-based payment models for pharmaceuticals. He is also a Professor of Medicine and Pharmacy at the University of Pittsburgh where he has mentored students, residents, and fellows. He received his medical degree from George Washington University and completed an internal medicine residency at University of Pittsburgh. Prior to UPMC, he worked as a staff physician and national leader in Veterans Affairs Pharmacy Practice and Policy for 18 years, where he contributed to several research and quality improvement initiatives. He also served as technical advisor for several national organizations including CMS, FDA, and US Pharmacopeia.



Director: Samuel Peasah, PhD, RPh, MBA

Samuel Peasah is a Director at the Center for Value-Based Pharmacy Initiatives, UPMC Health Plan and an Adjunct Associate Professor at University of Pittsburgh School of Pharmacy. He received his MBA and PhD from University of Florida, and he is a fellow of the CDC Prevention Effectiveness Fellowship-a post-doctoral fellowship in health economics. He has expertise in value-based contract negotiations, implementation, assessment, and reporting. and other quality-of care outcomes evaluation at UPMC Health Plan. Prior to his position at UPMC, he was faculty, director for the Center for Outcomes Research and Education, and director of post-graduate pharmaceutical fellowships at Mercer University College of Pharmacy in Atlanta Georgia. He has precepted and published with pharmacy students and residents at Mercer and continues to precept Pitt School of Pharmacy PharmD students and residents in health outcomes research.

#### **Previous Fellows**

#### Neetu Agashivala, MS

Global RWE Head, Cardiovascular Renal Metabolism, Novartis

#### Lauren Bartolome, PharmD

Director, HEOR I&I,

Pfizer, Inc.

#### Kelly Fee Bell, PharmD, MSPhr

Value Evidence Lead, GlaxoSmithKline

#### William Boyko, PharmD

Pharmacist Consultant,

P&C Pharma

#### Cat Bui, PharmD, PhD

Director, HEOR, Hematology,

AbbVie

#### Scott Bull, PharmD

Director, Clinical Development,

Johnson & Johnson

#### Beilei Cai, PhD, MA

Senior Director, US HEOR-Oncology,

**Novartis** 

#### Aaron Carabajal-Johnson, PharmD, MS

Senior Manager, HEOR

Inovalon

#### Jane Chang, MPH

Senior Director, Value and Evidence,

Pfizer, Inc.

#### Michelle Choi, PharmD

Medical Science Liaison-Immunology,

Sanofi

#### Paul C. Cockrum, PharmD, DPh

North America Director, Oncology HEOR,

Ipsen Biopharma

#### Arijita Deb, PhD

Director, Value Evidence and Outcomes,

GlaxoSmithKline

#### Laurence Djatche, PharmD, MS

Director, HEOR,

**Endo Pharmaceuticals** 

#### QuynhChau Doan, PhD, MS, RPh

Director, External Strategies HEOR,

AbbVie

#### Joseph Doyle, MBA

Pharmacy Manager,

Dr. G's Pharmacy

#### Batul Electricwala, PhD

Director, HEOR,

**Novartis** 

#### John Fastenau, PhD, MPH, RPh

Senior Director, Patient Reported Outcomes,

Janssen Pharmaceuticals

#### Feride Frech, PhD, MPH

Senior Director, HEOR & RWE,

Eisai, Inc.

#### Rahul Garg, PhD

Assistant Professor,

Chicago State University

#### Joseph Goble, PharmD, MS

Director, Value & Evidence Scientific Engagement - Field,

Janssen Pharmaceuticals

#### Boris Gorsh, PharmD, MS

Value Evidence Leader,

GlaxoSmithKline

#### Bill Grant, PhD

Associate Professor of Economics.

College of Business,

James Madison University

#### Amy Grogg, PharmD

Strategic Advisor,

Vesey Street Capital Partners

#### Kristy Hanson, PharmD, MS

Scientific Consultant, Value Demonstration.

United BioSource Corporation:

An Express Scripts Company

#### Peter Hur, PharmD, MBA

Director, Worldwide HEOR Inflammation and Immunology,

Pfizer, Inc.

#### Archi Jackson, PharmD

President,

A&S Healthcare Consulting and Analytics, Inc.

#### Tom Karagiannis, PharmD, MS

Director, Global Market Access and Pricing,

AbbVie

#### Jennifer Kim, PharmD

Director, Global Pricing and Market Access,

AstraZeneca

#### John Kim, PharmD

Executive Director, Head of Global Market Access,

Seagen

#### Nina Kim, PharmD, MS

Associate Director, Real World Value & Evidence,

Oncology,

Janssen Pharmaceuticals

#### Yoona Kim, PharmD, PhD

Co-founder and CEO,

Arine

#### John Ko, PharmD, MS

Senior Director, Value, Evidence & Development Strategy,

Beam

#### Amy Law, PharmD, MS

Director, HEOR,

Pfizer, Inc.

#### Junji Lin, PhD

Associate Director,

Jazz Pharmaceuticals

#### Jackie Lu, PharmD, MS

Executive Director of Marketing,

Pacira Pharmaceuticals

#### Mario Luong, PharmD, MPH

Director of Operations,

Optum

#### Geneen Graber Maxwell, PharmD

President and CEO, Dr. G's Pharmacy

#### Shilpa Mehta, PharmD

Head of Oncology Marketing - Asia Pacific, Merck & Co, Inc

#### Patrick Mends, PharmD

#### Jeannie Menz, PharmD

Director, Content Development and Training, Sandoz

#### Laetitia N'Dri, PharmD

Senior Manager US HEOR, Bristol Myers Squibb

#### Gilbert C. Ngan, PharmD

Pharmacist: Part D Benefits Analyst,

#### Cindy Nguyen, PharmD

Senior Associate Director, HEOR Value Evidence and Outcomes Liaison, Boehringer Ingelheim

#### Jennifer Nguyen, PharmD

Senior Manager, HEOR US Oncology Novartis

#### Lina Nol-Heiring, BS, MBA

Therapeutics Sales Specialist, LEO Pharma

#### Grace Oh, PharmD

Associate Director, WW Scientific Content and US Market Capabilities, Thoracic and Emerging Tumors, Bristol Myers Squibb

#### **Engels Obi, PhD**

Director, Global Outcomes Research and Value Evidence Strategy Team Lead, Merck

#### Jacqueline B. Palmer, PharmD, MBA

Director, Professional Promotions Marketing, Novartis

#### Jina Park, PharmD

Director, Advanced Analytics, Komodo Health

#### Siyeon Natalie Park, PharmD

Enterprise Pharmacy - Clinical Carepath, Geisinger

#### Shivangi Patel, PharmD

Senior Manager, Patient-Centered Outcomes Research, Global Market Access, Sarepta Therapeutics

#### Hoa T. Pham, PharmD

Senior Director, Field HEOR, Beigene

#### Ngan Pham, PharmD

Senior Consultant, IQVIA

#### Craig Plauschinat, PharmD, MPH

Director, HEOR & RWE, Eisai, Inc.

#### Shibani Pokras, MPH

Senior Director, Oncology Cell Therapy, GlaxoSmithKline

#### Karim Prasla, PharmD, MS

VP, Clinical Outcomes Advanced Analytics and Research, Magellan Health Services

#### Karina Raimundo, BS Pharmacy, MS

Director, HEOR, Genentech, Inc.

#### Swetha Raparla, MS

Analytics Consultant,

Cigna

#### David Ray, PharmD, MBA, MPH

Executive Director, Global HEOR, Karyopharm Therapeutics, Inc.

#### Seon Young Ryu, PharmD

Mom/Independent Consulting, Previously at Genentech

#### Rahul Sasané, PhD, MS, BPharm

Head – Global HEOR-RWE & Reimbursement, Cerevel Therapeutics, LLC

#### Veronica Sendersky, PharmD

Managing Director, Excellentia Pharma Consulting

#### Amishi Shah,

Associate Director, Oncology Digital Engagement & Channel Strategy, Merck

#### Hemal Shah, PharmD

President/Founder, Value Matters, LLC

#### Karishma Shelley, PharmD

Associate Director, HEOR - US Market, Oncology, Bristol Myers Squibb

#### Slaven Sikirica, MS

Senior Director,

Lexicon Pharmaceuticals, Inc.

#### Anh Singhania, PharmD

Senior Director, Health Systems & Outcomes, Medical Affairs

Intercept Pharmaceuticals

#### Liz Stanley Smart, MPH

Senior Associate Director, HEOR, Boehringer Ingelheim

#### **Bhavini Patel Srivastava, MS, BS Pharmacy**

Director, HEOR,

AbbVie

#### Kangho Suh, PharmD, PhD, MS

Assistant Professor, University of Pittsburgh

#### **Dusica Tasic, MS, BS Pharmacy**

Health Economics Manager, Global Marketing, GE Healthcare

#### Devi Thaker, PharmD, MS

Director, PharmacoAnalytics, Express Scripts

#### Ryan Thaliffdeen, PharmD, MS

Senior Manager, Global Value & Access Gilead

#### Melody Tran, PharmD, MS

Medical Outcomes Liaison, Abbott Laboratories

#### Yuen Tsang, PharmD, MPH

Associate Director, Real World Value & Evidence, Janssen Pharmaceuticals

#### Stuart Turner, MPH

Executive Director Global Real World Evidence & Data Science - Solid Tumors, Novartis

#### Stefan Varga, PharmD, MSc

Director, WW HEOR, Bristol Myers Squibb

#### Ashok Vegesna, PharmD, MS

Director, National Accounts (Central US), Novartis

#### Joel Wallace, PharmD, MPH, MBA

Head, Global HEOR, Market Access and Business Strategy, Exelixis

#### Alexandra Wallem, PharmD,

Associate Director: Outcomes Liaison, Eli Lilly

#### Pin Xiang, PharmD

Director of HEOR Value Demonstration - CNS, Boehringer Ingelheim

#### Esther Yi, PharmD, MS

Director, Value & Evidence Inflammation and Immunology Pfizer

#### Krista Yokoyama, PharmD

Senior Manager, Pharmacy Analytics, Blue Shield of California

#### Jing Yuan, PhD

Associate Professor, Fudan University

# **HEOR Fellowship Application Form**

Please type or p	print		Date		
Name:					
Address:	Last	First		MI	
	Street	City	State	Zip Code	
Phone:		Secondary			
Email:					
Undergraduate	and Graduate Degree(s) (c	late received or expected):			
Please check a	ams (Preferred Degrees ny site(s) of interest:		io Dhawa a a suti a la Causa		
	•	University of Texas at Austin/Novarti	•		
	•	lege of Population Health/Novartis I of Pharmacy/UPMC Health Plan/No	·		
• •	, ,	sion, application deadline is Oo novartis.com and include the followin	•	l1:59 pm EDT):	
Cover Letter		• CV			
	orm with first-year e(s) preference	• Email of 2	2 References		
If offered an int	erview, the following docur	nents will be requested:			
2 Letters of F	Recommendation (sent via	email from references) • Unofficial	l Transcript		
Requirement	:s:				
or a related disc research, healt	cipline (e.g., PharmD, PhD, I h economics, or another re	ocused on pharmacy, health services MPH, etc.). A background in pharmad lated field of research is preferred. E g in teams and independently.	cy or medicine and expe	rience in outcomes	
Please email	or send the required a	oplication materials to:			

Batul Electricwala, PhD, BPharm Director, HE&OR and HE&OR Fellowship Director Email: usheor.fellowship@novartis.com